CR20210616A - Formas de sales cristalinas de un inhibidor de cinasas - Google Patents
Formas de sales cristalinas de un inhibidor de cinasasInfo
- Publication number
- CR20210616A CR20210616A CR20210616A CR20210616A CR20210616A CR 20210616 A CR20210616 A CR 20210616A CR 20210616 A CR20210616 A CR 20210616A CR 20210616 A CR20210616 A CR 20210616A CR 20210616 A CR20210616 A CR 20210616A
- Authority
- CR
- Costa Rica
- Prior art keywords
- kinase inhibitor
- salt forms
- crystalline salt
- relates
- compound
- Prior art date
Links
- 150000003839 salts Chemical group 0.000 title abstract 3
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical class C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención está relacionada con las formas cristalinas de sales del Compuesto 1. La invención también está relacionada con composiciones farmacéuticas que comprenden las sales cristalinas sólidas del Compuesto 1. La invención está relacionada además con métodos de tratamiento de una enfermedad, un trastorno o un síndrome mediado al menos en parte por la modulación de la actividad <em>in vivo</em> de una proteína cinasa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856404P | 2019-06-03 | 2019-06-03 | |
| PCT/US2019/065980 WO2020247019A1 (en) | 2019-06-03 | 2019-12-12 | Crystalline salt forms of a kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210616A true CR20210616A (es) | 2022-03-22 |
Family
ID=69160360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210616A CR20210616A (es) | 2019-06-03 | 2019-12-12 | Formas de sales cristalinas de un inhibidor de cinasas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20230052703A1 (es) |
| EP (1) | EP3976587B1 (es) |
| JP (1) | JP7579281B2 (es) |
| KR (1) | KR102826380B1 (es) |
| CN (1) | CN113939503B (es) |
| AU (1) | AU2019449809B2 (es) |
| BR (1) | BR112021024300A2 (es) |
| CA (1) | CA3139148A1 (es) |
| CL (1) | CL2021003205A1 (es) |
| CO (1) | CO2021017343A2 (es) |
| CR (1) | CR20210616A (es) |
| DO (1) | DOP2021000236A (es) |
| ES (1) | ES3008963T3 (es) |
| GE (2) | GEAP202415849A (es) |
| IL (1) | IL288484A (es) |
| MA (1) | MA56001A (es) |
| MX (1) | MX2021014773A (es) |
| PE (1) | PE20220962A1 (es) |
| PH (1) | PH12021553020A1 (es) |
| SG (1) | SG11202111978VA (es) |
| WO (1) | WO2020247019A1 (es) |
| ZA (1) | ZA202108034B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEAP202415420A (en) * | 2018-01-26 | 2024-12-25 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| EP4631505A3 (en) * | 2018-12-13 | 2025-12-10 | Exelixis, Inc. | Crystalline forms and salt forms of a kinase inhibitor |
| AR127561A1 (es) * | 2021-11-03 | 2024-02-07 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
| JP2025500436A (ja) | 2021-12-22 | 2025-01-09 | エグゼリクシス， インコーポレイテッド | キナーゼ阻害剤の結晶性形態及び塩形態 |
| CN116751161A (zh) * | 2023-06-28 | 2023-09-15 | 中国人民解放军军事科学院军事医学研究院 | 喹啉类化合物及其制备方法、药物组合物及医药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2744997A1 (en) * | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| US7314622B2 (en) | 2005-04-15 | 2008-01-01 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| KR101538707B1 (ko) * | 2010-07-14 | 2015-07-22 | 베타 파머수티컬 컴퍼니 리미티드 | c-MET 티로신 키나제 억제제로서 유용한 신규 융합된 헤테로사이클릭 유도체 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US20180009758A1 (en) * | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| IL270780B2 (en) * | 2017-05-26 | 2025-04-01 | Exelixis Inc | Crystalline solid forms of salts of N–{4–[(7,6–dimethoxyquinolin–4–yl)oxy]phenyl}–N'–(4–fluorophenyl)cyclopropane–1,1–dicarboxamide, processes for preparation and methods of use |
| GEAP202415420A (en) * | 2018-01-26 | 2024-12-25 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| EP4631505A3 (en) * | 2018-12-13 | 2025-12-10 | Exelixis, Inc. | Crystalline forms and salt forms of a kinase inhibitor |
| CN109761899B (zh) * | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2019
- 2019-12-12 SG SG11202111978VA patent/SG11202111978VA/en unknown
- 2019-12-12 US US17/616,124 patent/US20230052703A1/en active Pending
- 2019-12-12 GE GEAP202415849A patent/GEAP202415849A/en unknown
- 2019-12-12 AU AU2019449809A patent/AU2019449809B2/en active Active
- 2019-12-12 GE GEAP201915849A patent/GEP20247655B/en unknown
- 2019-12-12 MX MX2021014773A patent/MX2021014773A/es unknown
- 2019-12-12 CR CR20210616A patent/CR20210616A/es unknown
- 2019-12-12 PH PH1/2021/553020A patent/PH12021553020A1/en unknown
- 2019-12-12 PE PE2021002015A patent/PE20220962A1/es unknown
- 2019-12-12 JP JP2021571744A patent/JP7579281B2/ja active Active
- 2019-12-12 CA CA3139148A patent/CA3139148A1/en active Pending
- 2019-12-12 MA MA056001A patent/MA56001A/fr unknown
- 2019-12-12 EP EP19836340.0A patent/EP3976587B1/en active Active
- 2019-12-12 CN CN201980097028.2A patent/CN113939503B/zh active Active
- 2019-12-12 ES ES19836340T patent/ES3008963T3/es active Active
- 2019-12-12 BR BR112021024300A patent/BR112021024300A2/pt unknown
- 2019-12-12 WO PCT/US2019/065980 patent/WO2020247019A1/en not_active Ceased
- 2019-12-12 KR KR1020217041796A patent/KR102826380B1/ko active Active
-
2021
- 2021-10-20 ZA ZA2021/08034A patent/ZA202108034B/en unknown
- 2021-11-17 DO DO2021000236A patent/DOP2021000236A/es unknown
- 2021-11-28 IL IL288484A patent/IL288484A/en unknown
- 2021-12-02 CL CL2021003205A patent/CL2021003205A1/es unknown
- 2021-12-16 CO CONC2021/0017343A patent/CO2021017343A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3976587B1 (en) | 2024-12-04 |
| IL288484A (en) | 2022-01-01 |
| CO2021017343A2 (es) | 2022-01-17 |
| AU2019449809B2 (en) | 2026-02-05 |
| SG11202111978VA (en) | 2021-11-29 |
| BR112021024300A2 (pt) | 2022-01-11 |
| ES3008963T3 (en) | 2025-03-25 |
| PH12021553020A1 (en) | 2023-08-23 |
| AU2019449809A1 (en) | 2021-12-16 |
| EP3976587A1 (en) | 2022-04-06 |
| WO2020247019A1 (en) | 2020-12-10 |
| MX2021014773A (es) | 2022-01-18 |
| GEAP202415849A (en) | 2024-03-11 |
| KR20220016117A (ko) | 2022-02-08 |
| JP7579281B2 (ja) | 2024-11-07 |
| MA56001A (fr) | 2022-04-06 |
| US20230052703A1 (en) | 2023-02-16 |
| CN113939503B (zh) | 2024-05-07 |
| JP2022535072A (ja) | 2022-08-04 |
| PE20220962A1 (es) | 2022-06-10 |
| EP3976587C0 (en) | 2024-12-04 |
| GEP20247655B (en) | 2024-08-26 |
| CA3139148A1 (en) | 2020-12-10 |
| DOP2021000236A (es) | 2022-04-18 |
| KR102826380B1 (ko) | 2025-06-26 |
| CL2021003205A1 (es) | 2022-09-30 |
| CN113939503A (zh) | 2022-01-14 |
| ZA202108034B (en) | 2025-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210375A (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa | |
| ZA202108034B (en) | Crystalline salt forms of a kinase inhibitor | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| PH12020552187A1 (en) | Pcsk9 antagonist compounds | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2021015262A (es) | Inhibidores de prmt5. | |
| EA201690752A1 (ru) | Ингибиторы g12c kras | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| EA201991884A3 (ru) | Ингибиторы g12c kras | |
| PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| EA200702339A1 (ru) | Замещенные амидные производные в качестве ингибиторов протеинкиназы | |
| MX2020012978A (es) | Sales de sepiapterina farmacéuticamente aceptables. | |
| CR20210460A (es) | Compuestos útiles en la terapia del vih | |
| MX2012003007A (es) | Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer. | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| MX2023010303A (es) | Metodo de modulacion de las vias de se?alizacion de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol. | |
| ZA202107777B (en) | Voruciclib polymorphs and methods of making and using thereof | |
| PH12019501566B1 (en) | Amide compounds and use thereof | |
| CR20230223A (es) | Composiciones farmacéuticas de un inhibidor de cinasa | |
| MX2024009648A (es) | Formas cristalinas de sal de n-(4-(4-(ciclopropilmetil)piperazin-1 -carbonil)fenil)quinolin-8-sulfonamida. | |
| EA202191653A1 (ru) | Кристаллические формы и солевые формы ингибитора киназы | |
| EA202192382A1 (ru) | Соединения, нацеленные на prmt5 | |
| ZA202300107B (en) | Pharmaceutically acceptable salts of sepiapterin |